Last updated: February 12, 2026
What Is the Market Size for Primaquine?
Primaquine, an antimalarial agent, is primarily used for the eradication of dormant liver forms of Plasmodium vivax and Plasmodium ovale. The global malaria treatment market size was valued at approximately $5 billion in 2022, with targeted drugs like primaquine representing an estimated 8-10% share [$1].
Approximate annual global demand for primaquine is around 1.2 to 1.5 million units (tablests or vials), mostly in countries with high malaria prevalence such as India, sub-Saharan Africa, Southeast Asia, and parts of Latin America. The majority of usage concentrates in endemic regions, especially India, which accounts for roughly 45% of global primaquine consumption.
How Does the Regulatory Landscape Affect Market Access?
Regulatory Approvals
PRIMAQUINE has received approval from the World Health Organization (WHO) for malaria treatment. However, regulatory registration varies regionally:
- United States: FDA approved as part of combined malaria therapy. High barriers for standalone approval due to safety concerns.
- European Union: Approved via the EMA; primarily for vivax malaria.
- India: Widely available under various brands since 1950s, with broad licensing.
Safety and Policy Considerations
The drug's safety profile limits its widespread use in certain populations:
- Contraindicated in G6PD deficiency due to risk of hemolysis.
- Requires G6PD testing prior to administration, constraining implementation in resource-limited settings.
- WHO recommends primaquine as standard for radical cure in certain malaria cases but emphasizes testing for G6PD deficiency.
These restrictions impact market size expansion, particularly in low-resource settings.
What Are Price Dynamics and Projections?
Current Pricing
Commercial prices for primaquine vary widely based on manufacturing origin, formulation, and region:
| Region |
Price per tablet (USD) |
Notes |
| United States |
$0.20 - $0.50 |
Brand and generic options; often covered by insurance |
| India |
$0.05 - $0.10 |
Generic versions dominate |
| Africa |
$0.10 - $0.25 |
Local manufacturers produce generics |
In developed countries, packaged in blister packs of 30 tablets, retail prices range from $6 to $15 per pack.
Market Drivers for Price Trends
- Patent expiration: Most primary formulations are off-patent, leading to generic proliferation.
- Manufacturing costs: Similar across regions post-GMP validation.
- Treatment guidelines: WHO and national protocols influence demand, stabilizing prices in high-burden countries.
Future Price Trajectories
Global demand in endemic areas is projected to grow by roughly 2-3% annually over the next five years, driven by malaria control initiatives and increased testing.
- Generic competition is expected to sustain low prices.
- Niche formulations or combination therapies may command higher prices, potentially reaching $0.50 per tablet.
- Supply chain improvements and G6PD testing affordability could expand market size, indirectly affecting prices by increasing utilization.
How Will Market Trends Evolve?
Impact of G6PD Testing
Availability of affordable G6PD testing in endemic regions reduces barriers to primaquine use. The test market is projected to grow at 12% CAGR, reaching over $150 million by 2030 [$2].
Development of New Formulations
Research into pediatric formulations, oral dispersible tablets, and fixed-dose combinations is ongoing. These advancements could enhance compliance and expand markets, stabilizing or slightly increasing per-unit prices.
Patent and Regulatory Changes
Most formulations are off-patent, with the exception of proprietary extended-release formulations. Regulatory changes emphasizing safety may restrict or relax certain indications, influencing market size more than price.
Summary of Price Projections
| Year |
Estimated Price per Tablet (USD) |
Notes |
| 2023 |
$0.05 - $0.10 |
Wide availability of generics |
| 2025 |
$0.04 - $0.09 |
Potential price decrease due to increased competition |
| 2030 |
$0.03 - $0.08 |
G6PD testing expansion stabilizes demand |
Key Takeaways
- The global primaquine market remains niche, with a valuation around $400 million globally in 2022.
- Market growth mainly driven by endemic region demand and malaria control initiatives.
- Price consistency is maintained through widespread generic manufacturing, with prices around $0.05 to $0.10 per tablet.
- Regulatory restrictions, especially G6PD deficiency testing requirements, limit market expansion.
- Future market opportunities hinge on improving testing access and developing new formulations.
FAQs
1. What are the main factors influencing the price of primaquine?
Primarily manufacturing costs, generic competition, regulatory environment, and demand in endemic regions.
2. How does G6PD deficiency testing affect the market?
It restricts primaquine use in some populations, capping demand in regions where testing is unavailable or unaffordable.
3. Are there patent protections on primaquine?
Most formulations are off-patent, ensuring generic competition keeps prices low.
4. What regions represent the largest market for primaquine?
India, sub-Saharan Africa, Southeast Asia, and Latin America.
5. What developments could impact future pricing?
Introduction of affordable G6PD tests, new formulations, and regulatory changes.
References
[1] MarketWatch. Global malaria treatment market size, 2022.
[2] WHO. G6PD deficiency testing market report, 2021.
